401 related articles for article (PubMed ID: 9135852)
1. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
[TBL] [Abstract][Full Text] [Related]
11. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels.
Kashiwabara K; Nakamura H; Esaki T
Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J
Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
[TBL] [Abstract][Full Text] [Related]
13. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma.
Rapellino M; Niklinski J; Pecchio F; Furman M; Baldi S; Chyczewski L; Ruffini E; Chyczewska E
Eur Respir J; 1995 Mar; 8(3):407-10. PubMed ID: 7540561
[TBL] [Abstract][Full Text] [Related]
15. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Mady EA
Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
18. Tumor markers kinetic in malignant lung neoplasms.
Cristofori R; Aimo G; Mengozzi G; Oliaro A; Revello F; Rapellino M
J Cardiovasc Surg (Torino); 1999 Apr; 40(2):299-305. PubMed ID: 10350122
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A
Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]